НЕФРОПАТИЯ ОЖИРЕНИЯ В ПЕДИАТРИИ
https://doi.org/10.24884/1561-6274-2013-17-6-37-45
Аннотация
В обзоре приводятся сведения о морфологии и функции почек у детей при ожирении. Обсуждается влияние и взаимосвязь многочисленных патогенетических факторов, действующих на работу почки. Отмечено своеобразие нефропатии ожирения у детей по сравнению с взрослым организмом.
Об авторах
Н. Н. СмирноваРоссия
Кафедра педиатрии
197022, Санкт-Петербург, ул. Л.Толстого, д. 6/8
Н. Б. Куприенко
Россия
Кафедра педиатрии
Список литературы
1. World Health Organization. Childhood overweight and obesity. http://www.who.int/dietphysicalactivity/childhood/en/ 2013
2. Steven MS, Jatinder B (ed). Obesity in children. MBBS// emedicine medscape.com/article/985333-overview 2012
3. Overweight, obesity and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52(1): 39-48
4. Freemark M. Pediatric Obesity: Etiology, Pathogenesis, and Treatment. Humana Press, New York, 2010; 27-30
5. Шабалов НП (ред). Педиатрия. Учебник для медицинских вузов. Спец Лит, СПб., 2010; Приложения, 880
6. Lahti-Koski M, Gill T. Defining Childhood Obesity. Pediatr Adolesc Med Basel Karger 2004; 9: 1-19
7. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006; 49: 270-283
8. Schwimmer JA, Markowitz GS, Valeri AM et al. Secondary focal segmental glomerulosclerosis in non-obese patients with increased muscle mass. Clin Nephrol 2003; 60(4): 233-241
9. Praga M, Hernandez E, Herrero JC et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118
10. Carolin LA, Rodriguez MM. Obesity-related Nephropathy in Children. Pediatr Health 2009; 3(2): 141-153
11. Serra A, Romero R, Lopez D et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008; 73: 947-955
12. Rea DJ, Heimbach JK, Grande JP et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006; 70: 1636-1641
13. Kato S, Nazneen A, Nakashima Y et al. Pathological influence of obesity on renal structural changes in chronic kidney disease. Clin Exp Nephrol 2009; 13: 332-340
14. Neeraja KH, Markowitz GS, Anthony MV et al. Obesityrelated glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
15. Nesauro M, Franzese O. Review Article «Chronic Kidney Disease, Obesity, and Hypertension: The Role of Leptin and Adiponectin». Hindawi Publishing Corporation Int J Hypertension 2012; Article ID 943606, 7 pages doi: 10.1155/2012/943605
16. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Medical Sci 2001; 47(3): 141-159
17. Yamagishi SI, Edelstein D, Du XL et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276(27): 25096-25100
18. Werner N, Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin. Ateriosclerosis, Thrombosis and Vascular Biology 2004; 24(1): 7-9
19. Wolf G, Hamann A, Han D.C. et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999; 56(3): 860-872
20. Ballerman BJ A role for leptin in glomerulosclerosis. Kidney Int 1999; 56(3): 1154-1155
21. Chagnac A, Weinstein T, Korzerts A, et al. Glomerular hemodynamic in severe obesity. Am J Physiol 2000; 278: F817-F822
22. Adamczak M, Wiecek A, Funahashi J et al. Deceased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertesion 2003; 16 (1): 72-73
23. Yan KCB, Xu A, Chow WS et al. Hypoadipinectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrin Metab 2004; 89(2): 765-769
24. Kostis V, Stabouli S, Papakatsika S et al. Mechanisms of obesity-induced hypertension. Review. Hypertension Res 2010; 33: 386-393
25. Yano Y, Hoshide S, Ishikawa J et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertension 2007; 9(10): 775-782
26. Kacso IM, Bondor CI, Kacso G. Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients. Scand J Clin Lab Investigation 2012; 72 (4): 333-339
27. Onyango BS. The effects of the adipocyte-secreted proteins resistin and visfatin on the pancreatic beta-cell. A thesis submitted in partial fulfillment of the requirements of the University of Wolverhampton for degree of Doctor of Philosophy 2009
28. Hall JE, Brands MW, Henegar JR, Shek EW Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998; 25: 58-64
29. Coward RJM, Welsh GI, Kopziell A et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56: 1127-1135
30. Naumnik B, Mysliwiec M. Renal consequences of obesity. Med Sci Monit 2010; 16(8): RA163-170
31. Greenfield JR, Miller JW, Keogh JM et al. Modulation of blood pressure by central melanocortinergic pathways. NEJM 2009; 360: 44-52
32. Chagnac A, Herman M, Zingerman B et al. Obesityinduced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008; 23: 3946-3952
33. Bosma RJ, Van Der Heide JJ Oosterop EJ et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004; 65: 259-265
34. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol renal Physiol 2000; 278: F817-F822
35. Ichikawa I, Hoyer JR, Seiler MW et al. mechanism of glomerulotubular balance in the setting of heterogeneous glomerular injury. Preservation of a close functional linkage between individual nephrons and surrounding microvasculature. J Clin Invest 1982; 69: 185-198
36. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulocentric view. J Am Soc Nephrol 2003; 14:530-537
37. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41: 625-633
38. Chiolero A, Maillard M, nussberger J et al. Proximal sodium reabsorption: an independent determinant of blood pressure response to salt. Hypertension 2000; 36: 631-637
39. Arfvidsson B, Eklof b, Balfour J. Iliofemoral venous pressure correlates with intraabdominal pressure in morbidity obese patients. Vasc Endovascular Surg 2005; 39:505-509
40. Karlsson C, Lindell K, Ottosson M et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83(11):3925-3929
41. Sugrue M. Abdominal compartment syndrome. Curr Opin Crit Care 2005; 11:333-338
42. D’Elia JA, Roshan B, Maski M, Larry A. Manifestation of Renal disease in obesity: pathophysiology of obesity-related dysfunction. Int J Nephrology and Renovascular Disease Dovepress 2009; 2:39-49
43. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70: 1560-1566
44. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for Chronic kidney disease? J Am Soc Nephrol 2004; 15: 2775-2791
45. Weinberg JM «Lipotoxicity.» Kidney Int 2006; 70: 1560- 1566
46. Avramoglu RK, Qiu W, Adeli K. «Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci 2003; 8: d464-d476
47. Wahba IM, Mak RH. Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease. Clin J Am Soc Nephrol 2007; 2:550-562
48. Ruan XZ, Moorhead JF, Fernando R. Regulation of inflammatory mediators and transcription factors. Biochem Soc Trans 2004; 32: 88-91
49. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006; 55: 2502-2509
50. Shankar SS, Steinberg HO. FFAs: Do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 2005; 5: 30-35
51. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: From the perspective of a vicious triangle. Int J Obes relat metab Disord 2002; 26 (Suppl 20: S28-S38)
52. Thomas ME, Morrison AR, Schreiner GF Metabolic effects of fatty acids exacerbate tubulointerstitial injury in proteinoverloaded proteinuria. Am J Physiol Renal Physiol 2002; 283: F640-F647
53. Arici M, Chana R, Lewington A, Brown J, Brunskill NJ Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptorgamma. J Am Soc Nephrol 2003; 14: 17-27
54. Hajiwara S, Makita Y, Gu l et al. Eicosopentanoic acid ameliorates diabetic nephropathy of type 2 diabetic KKay/TA mice: involvement of MCP1 suppression and decreased ERK1/2 and p 38 phosphorylation. Nephrol Dial transplant 2006; 21: 605-615
55. Hirosumi J et al. A central role for JNK in obesity and insuline resistance. Nature 2002; 420: 333-336
56. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
57. Wisse BE. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800
58. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005; 111: 1448-1454
59. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, Li L. Obesityrelated glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006; 147: 44-50
60. Way JM et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insuline-sensitive tissues. Endocrinology 2001; 142: 1269-1277
61. Малявская CB, Лебедев АВ, Терновская ВА. Значение хронической бессимптомной гиперурикемии как маркера атерогенного риска у детей. Кардиология 2007; 3: 62-67
62. Lauren F L, Navas-Acien A, Tammy M, Brady et al. Uric Acid Level and Elevated Blood pressure in US Adolescents. prehyper. ahajournals.org/content/early/2012/02/21/HYPERTENSIONAHA.111.183244.abstract
63. Veeraish Chauhan et al. The Obesity Epidemic and Kidney disease: a Literature Review. In:Manisha S,ed. Diseases of Renal parenchyma. Published on line 16 March, 2012; 5-17
64. Chikako Oyama, Nsutomu Takahashi, Mika Oyamada et al. «Serum Uric Acid as an Obesity-Related Indicator in Early Adolescence. Tohoku J Exp Med 2006; 209: 257-262
65. Wright AF, I. Rudan ND, Hastie H, Campbell A. ‘Complexity’ of Urate transporters. Kidney Int 2010; 78:446-452
66. Миняйлова НН, Казакова ЛМ. Диагностические аспекты гипоталамического и метаболического синдромов у детей. Педиатрия 2002; 4: 98-101
Рецензия
Для цитирования:
Смирнова Н.Н., Куприенко Н.Б. НЕФРОПАТИЯ ОЖИРЕНИЯ В ПЕДИАТРИИ. Нефрология. 2013;17(6):37-45. https://doi.org/10.24884/1561-6274-2013-17-6-37-45
For citation:
Smirnova N.N., Kuprienko N.B. DIABETIC NEPHROPATHY IN PEDIATRICS. Nephrology (Saint-Petersburg). 2013;17(6):37-45. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-6-37-45